Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid

Epilepsy and Behavior

Volumn 22, Issue 3, 2011, Pages 461-468

  Pessah, Neta ^a   Yagen, Boris ^a,b   Hen, Naama ^a   Shimshoni, Jakob A ^a   Wlodarczyk, Bogdan ^c   Finnell, Richard H ^c   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

6 Hz psychomotor seizure test; Glycinamide conjugates; Maximal electroshock seizure test Subcutaneous metrazol seizure test; N methoxy derivatives; Valproic acid isomers and analogues

Indexed keywords

ANTICONVULSIVE AGENT; GLYCINAMIDE; N METHOXY AMIDE DERIVATIVE; N METHOXY DIISOPROPYLACETAMIDE; N METHOXY DIISOPROPYLGLYCINAMIDE; N METHOXY PROPYLISOPROPYLACETAMIDE; N METHOXY VALNOCTAMIDE; N METHOXY VALNOCTYLGLYCINAMIDE; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; ELECTRIC SHOCK; FEMALE; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; SEIZURE; TERATOGENICITY; TOXICITY TESTING;

AMIDES; ANIMALS; ANTICONVULSANTS; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROSHOCK; FEMALE; ISOMERISM; MALE; MICE; NEURAL TUBE DEFECTS; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 80055000175     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.08.026     Document Type: Article

References (47)

1. Bourgeois F.D.B. Valproic acid: clinical efficacy and use in epilepsy. Antiepileptic drugs 2002, 808-817. Lippincott Williams & Wilkins, New York. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
2. Brodie M.J. Do we need any more new antiepileptic drugs?. Epilepsy Res 2001, 45:3-6.
3. Loscher W. Basic pharmacology of valproate. CNS Drugs 2002, 16:669-694.
4. Bialer M., Twyman R.E., White H.S. Correlation analysis between anticonvulsant-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004, 5:866-872.
5. Kaneko S., Battino D., Andermann E., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
6. Zimmerman H.J., Ishak K.G. Valproate-Induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982, 2:591-597.
7. Sussman N.M., Mclain L.W. A direct hepatotoxic effect of valproic acid. JAMA 1979, 242:1173-1174.
8. Nau H., Hauck R.S., Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991, 69:310-321.
9. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005, 4:781-786.
10. Koenig S.A., Buesing D., Longin E., et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47:2027-2031.
11. Battino D., Tomson T. Management of epilepsy during pregnancy. Drugs 2007, 67:2727-2746.
12. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010, 9:68-83.
13. Granneman G.R., Wang S., Kesterson J.W., McHinist J.M. The hepatotoxicity of valproic acid and its metabolism in rats: II. Intermediary and valproic acid metabolism. Hepatology 1984, 4:1153-1158.
14. Bojic U., Elmazar M.M.A., Hauck R.-S., Nau H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 1996, 9:866-870.
15. Bojic U., Ehlers K., Ellerbeck U., et al. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. Eur J Pharmacol 1998, 354:289-299.
16. Tang W., Abbott F.S. Characterization of thiol-conjugated metabolites of 2-propyl-4-pentenoic acid (4-ene-VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry. J Mass Spectrom 1996, 13:926-936.
17. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991, 20:114-122.
18. Hadad S., Bialer M. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm Res 1995, 12:905-910.
19. Levi M., Yagen B., Bialer M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm Res 1997, 14:213-217.
20. Isoherranen N., Yagen B., Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. Curr Opin Neurol 2003, 16:203-211.
21. Seiler N., Sarhan S. Synergistic anticonvulsant effects of a gaba agonist and glycine. Gen Pharmacol 1984, 15:367-369.
22. Toth E., Lajtha A. Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem Res 1984, 9:1711-1718.
23. Liu Z., Seiler N., Marescaux C., Depaulis A., Vergnes M. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. Eur J Pharmacol 1990, 182:109-115.
24. Isoherranen N., Woodhead J.H., White H.S., Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia 2001, 42:831-836.
25. Hadad S., Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos 1997, 18:557-566.
26. Hovinga C.A. Novel anticonvulsant medications in development. Expert Opin Investig Drugs 2002, 11:1387-1406.
27. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., Tomson T. Progress report on new antiepileptic drugs: a summary of the eighth Eilat conference (Eilat VIII). Epilepsy Res 2007, 73:1-52.
28. Bialer M., Yagen B. Valproic acid: second generation. Neurotherapeutics 2007, 4:130-137.
29. Bialer M., Haj-Yehia, Barzaghi N., Pisani F., Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990, 38:289-291.
30. Barel S., Yagen B., Schurig V., et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997, 61:442-449.
31. Bersudsky Y., Applebaum J., Gaiduk Y., et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord 2010, 12:376-382.
32. Haj-Yehia A., Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 1988, 77:831-834.
33. Haj-Yehia A., Hadad S., Bialer M. Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide. Pharm Res 1992, 9:1058-1063.
34. Bialer M., Haj-Yehia A., Badir K., Hadad S. Can we develop improved derivatives of valproic acid?. Pharm World Sci 1994, 16:2-6.
35. Kaufmann D., Yagen B., Minert A., et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010, 52:1228-1236.
36. Pessah N., Bialer M., Wlodarczyk B., Finnell R.H., Yagen B. Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem 2009, 52:2233-2242.
37. Sobol E., Bialer M., Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. synthesis and evaluation of anticonvulsant activity of its amide derivatives. J Med Chem 2004, 47:4316-4326.
38. Sobol E., Yagen B., Lamb J.G., et al. Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. Epilepsy Res 2007, 73:75-84.
39. Shimshoni J.A., Yagen B., Pessah N., Wlodarczyk B., Finnell R.H., Bialer M. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid. Epilepsia 2008, 49:1202-1212.
40. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., Wolf H.N. Discovery and preclinical development of antiepileptic drugs. Antiepileptic drugs 2002, 36-48. Lippincott Williams & Wilkins, New York. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
41. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
42. Finnell R.H., Bennett G.D., Karras S.B., Mohl V.K. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988, 38:313-320.
43. Finnell R.H., Wlodarczyk B., Craig J.C., Piedrahita H., Bennett G.D. Strain dependent alteration in the expression of folate pathway genes following teratogenic exposure to valproic acid in mouse model. Am J Med Genet 1997, 70:303-311.
44. Emma S.J., Williams M. Challenges in the search for drugs to treat central nerve systems disorders. J Pharmacol Exp Ther 2009, 329:401-411.
45. Chapman M.G., Smith M., Hirsch N.P. Status epilepticus. Anaesthesia 2001, 56:648-659.
46. Morrell M.J. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996, 37(Suppl. 6):S34-S44.
47. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69:273-294.